Missing Information
  • A System Error Has Occured:0177 - Failed to Load All Sections.
Form Type:  8-K
Filing Date:  12/26/2013 
CIK:  0001176309 
PO BOX 39098
City, State, Zip:  JERUSALEM,  91390 
Telephone:  011 972-2-566-0001 
Fiscal Year:  08/31 
Last Trade
Last Trade: 
0.09 (0.85%)  
Trade Time: 
09:30 AM EST  
Market Cap: 
Trade ORMP now with 

© 2017  
Description of Business
We are a pharmaceutical company currently engaged in the research and development of innovative pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Oral insulin: We are seeking to revolutionize the treatment of diabetes through our proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). We completed a Phase IIb clinical trial on 180 type 2 diabetic patients that was conducted in 33 sites in the United States. This double-blind, randomized, 28-day clinical trial was conducted under an Investigational New Drug application, or IND, with the U.S. Food and Drug Administration, or FDA. The clinical trial, designed to assess the safety and efficacy of ORMD-0801, investigated ORMD-0801 over a longer treatment period and had statistical power to give us greater insight into the drug's efficacy.